Dr. David E. Zepeda Reyes
Dermatologist and clinical researcher
With over 15 years of experience as Principal Investigator, I have successfully led my research center in conducting clinical trials across various medical specialties, ensuring the integrity and accuracy of the obtained data.
My leadership has been crucial in coordinating multidisciplinary teams, guaranteeing the highest ethical and regulatory standards. I have actively contributed to publishing results in scientific journals. National and international speaker.
I am committed to excellence and innovation in clinical research, continuously seeking opportunities for professional development and contributing to the advancement of medical knowledge.
Education
-
UNIVERSIDAD FRANCISCO MARROQUÍN
Dermatologist 2001-2004 -
UNIVERSIDAD EVANGÉLICA DE EL SALVADOR
Doctor in Medicine 1992-2001
LANGUAGES
-
Spanish
Native -
English
Bilingual -
Portuguese
Intermediate Level -
French
Basic Level
Personal Experience
Work Experience
CENTRAL AMERICAN RESEARCH UNITED (CARU)
Founder and President 2023-Present
Coordinating, establishing, and overseeing clinical research centers in El Salvador, Costa Rica, and Guatemala. Building relationships with researchers, medical institutions, sponsors of clinical studies, and regulatory agencies. Developing and implementing operational policies and procedures to ensure efficiency, quality, and ethical standards in clinical trial management.ZEPEDA RESEARCH
Chief Medical and Executive Officer 2008-Present
Principal investigator responsible for planning, logistics, and development of clinical research protocols. Supervising the execution of clinical trials, including patient recruitment and follow-up, as well as data collection. Ensuring the quality and integrity of clinical data by adhering to Good. Clinical Practice standards (ICH-GCP) and other regulatory requirements.ZEPEDA DERMATOLOGY
Medical Director 2005-Present
Extensive experience in providing quality dermatological healthcare, with a focus on personalized care and comprehensive management of patients’ skin needs, providing precise diagnoses, dermatological surgery procedures, cosmetic facial rejuvenation procedures, and evidence-based treatments.UNIVERSITY PROFESSOR
Head of the Dermatology Department at Nueva San Salvador University 2018-2020
Supervising, coordinating, and teaching the dermatology subject at the university, ensuring comprehensive education for medical students in the dermatological field.MEDICAL ASSOCIATIONS
-
ASOCIACIÓN DE PROFESIONALES MEDICOS DE LA DERMATOLOGÍA (PRODERMA)
Founding Member, President of the association in 2016 -
ASOCIACIÓN DERMATOLÓGICA DE EL SALVADOR
Member -
COLEGIO IBEROAMERICANO DE DERMATOLOGÍA (CILAD)
Member -
SOCIEDAD CENTROAMERICANA DE DERMATOLOGÍA
Member -
SOCIEDAD LATINOAMÉRICANA DE PSORIASIS
Member
CONDUCTED CLINICAL TRIALS
- A randomized, observer-blinded, placebo-controlled study on the safety and efficacy of twice-daily application of SM-030 Gel 0.64% vs. Gel SM-030 0.08% vs. Placebo Gel in adults with melasma. Dermbiont Inc. Phase III. 2024-present
- Safety and efficacy of Fusidic acid in patients with secondary skin infections. Taro Pharm, Phase IV. 2023.
- Adaptive open-label design study to explore the Safety and Efficacy of multiple treatment regimens with Akt Inhibitor SM-020 Gel in 1.0% and 0.1% formulations in subjects with seborrheic keratosis. Dermbiont Inc. Phase III. 2021-present
- Safety and Efficacy of twice-daily application o Ruboxistaurin Gel vs. Vehicle Gel vs. Hydroquinone Cream in sun-exposed and sun-protected skin of adults. DermBiont, Inc. Phase IIA. 2022-2023
- Safety and Efficacy of SCD-044 in the treatment of moderate to severe atopic dermatitis. Taro Pharm, Phase IIB. 2022-present
- Safety and Efficacy of SCD-044 in the treatment of moderate to severe psoriasis. Taro Pharm, Phase IIB. 2022-present
- Safety and Efficacy of Mupirocin in secondary infections by Taro Pharm Phase III 2018-2019. (FDA Audit on 4th November to 9th November, 2019, Satisfactory result, no finding 483)
- Safety and Efficacy of Fusidic acid in patients with Impetigo. Novum Pharm. Phase III. 2018-2019
- Safety and Efficacy of Ivermectin in patients with Pediculosis. Novum Pharm. Phase III. 2018 Safety and Efficacy of Desoximetasone in Atopic Dermatitis. Novum Pharm. PK Study. 2017-2019
- Safety and Efficacy of Desoximetasone in Pediatric Psoriasis. Novum Pharm. PK Study. 2017-2019.
- Safety and Efficacy of permethrin in patients with scabies. Novum Pharm. Phase III 2015-2016
- Safety and Efficacy of Favipiravir in patients with Influenza. PPD. Phase III 2013-2015
- Safety and Efficacy of Mupirocin in secondary infections. Novum Pharma. Phase III 2011
- Safety and Efficacy of Isotretinoin in acne (Isoface) phase IV Procaps. 2006″
CERTIFICATIONS
- Good Clinical Practices (GCP) NIDA Clinical Trials Network. May 2024 Certificate valid until May 2027
- Good Clinical Practices (GCP) NIDA Clinical Trials Network. 2021-2024
- Protecting Human Research Participants Training. National Institute of Health 2013.
- IATA Certification Mayo Clinic, Mayo Medical Laboratories 2013.
- Transporting Dangerous Goods, Mayo Clinic; Mayo Medical Laboratories. Certification for the State of Florida and California 2013
- First Presencial Course of Good Clinical Practices in Investigation CIDAL- Colegio Médico de El Salvador 2012.
WHY CHOOSE US:
- Simple Solutions, Big Impact: We believe that the best solutions are often the simplest. By focusing on practical, straightforward approaches, we're able to deliver meaningful results in the clinical trials that our site performs having a real impact on people's lives.
- Passion for Progress: We're passionate about progress and always looking for ways to move forward. Whether it's through continuous improvement, ongoing learning, or embracing change, we're committed to making progress every day to ensure high quality data and fast results.
- Customer-Centric Approach: We're here to serve our customers and meet their needs. Your success is our success, and we'll go above and beyond to ensure you have everything you need to achieve your clinical success.
you have questions?